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SI]MMARY AND CONCLUSIONS
Cisplatin (CDDP) is an effective chemotherapeutic agent for the treatment of a
variety of human cancers. Drug toxicity and resisLance are the lirnitations to its
application in clinical practice.
In this thesis a number of strategies to overcome these problems are
investigated. Among these are the combination of cisplatin with the cell
differentiation inducing agent retinoic acid, the combination of cisplatin with
radiotherapy, the application of cisplatin in hyperthermic isolated regional
perfusion and the development of new platinum analogues. In chapter 1 these
options are reviewed. From the literature, it is concluded that, although interesting
effects are documented in patient studies, until now the overall response rate of
differentiation induction alone in cancer therapy is disappointing. One method to
improve this, might be the cornbination of differentiation induction therapy with
cytotoxic chemotherapy. In chapter 2, the combined effect of the differentiation
inducer all-trans retinoic acid (RA) pretreatment and cisplatin or etoposide (VP-16)
were studied in the murine embryonal carcinoma cell line PCC4. It was found that
all-trans retinoic acid pretreatment for 96 h at concentrations of lO-e to 10-6 M
induces early somatic differentiation, as studied by the expression of differentiation
and embryonal carcinoma cell specific markers. Furthermore, 96 h all-trans
retinoic acid pretreatment with concentrations as low as l0e to 10 7 M enhances
both cisplatin and etoposide cytotoxicity in PCC. by a factor 1.9-3.0. Enhanced
cisplatin cytotoxicity was not attributable to changes in cellular drug concentration
or platinum-DNA binding. However, with etoposide cellular drug concentrations
were found to be increased by a factor 2.0-4.5 upon all-trans retinoic acid
pretreatment. Furthermore, all-trans retinoic acid pretreatment increased
topoisomerase I activity by a factor 2 whereas the activity of topoisomerase II,
being the biological target of etoposide, was found to be unaffected. These findings
might explain enhanced etoposide cytotoxicity upon all-trans retinoic acid pretreat-
ment.
In chapter 3, a comparative study of three intraperitoneal 13-cis retinoic
acid (13cRA) formulations in rats is presented. 13-cis Retinoic acid (2.5 mgl360 g
of body weight) was administered as an alkaline solution, suspended in corn oil, or
as a mixture with polysorbate 80. The alkaline solution was also given
intravenously. The mean elimination rate constant, calculated from the iv data, was
0.72 X 0.088 h-t. The mean peak concentration in plasma and the mean time to
reach this maximum were 14 mg/L and 0.5 h, 22 mglL and 2 h, and l0 mg/L and
t h for the drug administered as an alkaline solution, suspended in corn oil, and as
a mixture with polysorbate 80, respectively. The inean areas under the
concentration time curve (concentration in plasma versus time) were 34.9 + 8.78
mg.h/L for the iv dose and 34.1 + 9.97,62.4 + 32.3, and 25.9 + 12.0 mg.hlL
for the respective intraperitoneal doses. The alkaline solution given intraperitoneal-
ly showed a plasma concentration prohle similar to that of the solution admi-
nistered iv and is considered to be the formulation of choice among those tested.
Chapter 4 describes a phase I dose escalation study with 20-30 rng cisplatin
per liter limb volume administered during I h isolated limb perfusion under
hyperthermic onditions (39-40'C) in nine patients with lower extremity tumors.
After 60 min perfusion a decrease of 54.3 +' 12.4 %,79.9 + 14.7 % and79.2 +
4.2 Vo of the concentration of total platinum (Pt), ultrafilterable Pt and cisplatin in
the perfusate were observed respectively. The fraction free Pt decreased from 1.04
+ 0.21at t :  0 min to 0.40 + 0.08 at t :  60 min and is high compared to 0.05-
0.10 at normal iv infusion. This might be of great importance as protein binding of
cisplatin destroys most, if not all, of its cytotoxicity. Mean maxitnal leakage from
the perfused limb to the patients circulation, determined with radioactive albumin,
was 3.3 % and patients systemic total Pt concentrations varied from <0.1-4.2
mg/L. These data suggest hat in isolated limb perfusion high drug levels can be
attained in the perfusate with relatively low leakage to the patients systemic
circulation. Furthermore, the method shows substantial drug extraction by the
perfused limb which was confirmed by detectable tissue Pt concentrations in tumor
and surrounding normal tissues (skin, fat, muscle) and might allow high platinum
exposure of a tumor in a perfused limb. The maxirnurn tolerated dose with this
procedure was 275 mg showing considerable erythema and/or oedema with some
blistering and motor-sensory neuropathy as signs of local toxicity. No systernic
toxicity was observed.
Chapter 5, 6 and 7 deal with the new third generation cisplatin analogue
lobaplatin (1,2-diaminomethyl-cyclobutane-platinurn(II)-lactate), a drug which has
shown activity in a number of human cisplatin sensitive as well as resistant cell
lines and experimental tumors. Chapter 5 describes a study on the chernical
stability of lobaplatin in intravenous solutions determined by an accelerated stability
testing experiment. A selective high performance liquid chrornatographic rnethod
with UV detection, using a Supelcosil LC-l 5-pm column and a mobile phase
consisting of phosphate buffer and acetonitril, was developed for this study. Shelf
lives (defined as 5% loss of parent drug at 200 mglL in nornral saline) of 41.6;
13 .2 ;5 .7  and 0 .15  h  were  ca lcu la ted  a t  4 ,22 ,37  and 121"C respec t ive ly .
Dissolved in dextrose 5% the drug was found to be more unstable in comparison to
normal saline, whereas in Ringer's lactate it was found as stable as in normal
saline. There was no influence of light on lobaplatin stability.
The plasma pharmacokinetics of total and free platinurn (deterrnined by
flameless atomic absorption spectroscopy) and of free lobaplatin (by HPLC) in
seven patients with advanced ovarian carcinoma is described in chapter 6. Patients
received 50 mgim2 or 30 mg/m2 1in one patient with renal function impairment)
administered as a short term infusion (10 min). Plasma levels of total Pt show an
initial distribution with a mean half life of 16.6 t 9.6 min followed by a second
phase of 135 + 46 min. For ultrafilterable Pt these were 6.1 + 3.0 min and 64.5
+ 10.7 min respectively and for ultrafilterable lobaplatin they were 11.7 t 10.0
min and 84.1 + 32.1 min respectively. The mean plasma clearances were 9.7 t
1.2, 13.6 t 3.9 and 18.0 t 10.9 ht for total Pt, ultrafilterable- Pt and lobaplatin
respectively. The fraction free Pt was initially 88.3 + 12.6% and decreased to
49.7 + 14.6% at240 min postinfusion, which is very high compared to cisplatin
and carboplatin. Free Pt was essentially present as intact lobaplatin. Four hours
after the end of the infusion 54.4 + 5.0% and after 24 h, 73.0 + 3.6% of the Pt
dose was excreted in the urine, which is fast in comparison to cisplatin and
carboplatin.
Continuous infusion of drugs might reduce toxicity by avoiding high peak
levels in plasma while attaining similar drug exposure of the tumor and therefore
might improve the therapeutic index. In chapter 7, a phase I trial with continuous
infusion of lobaplatin for 72 h is presented in eleven patients who received a dose
ranging from 30-60 mg/m2 over 72 h every four weeks. All patients were evaluable
for toxicity and eight for tumor response. Thrombocytopenia was the dose-limiting
toxicity, with WHO grade III occurring in 3 out of 6 patients at 45 mglnllT2 h and
WHO grade IV in 2 out of 2 patients at 60 mglrfil72 h. Two patients developed a
symptomatic anemia during their second and third course. Leukocytopenia was
mild, as was nausea and vomiting. Phlebitis at the infusion site was found in three
patients. During this study there were no signs of renal, neuro- or ototoxicity. One
patient, pretreated with three different platinum complexes achieved a partial
response, now lasting for more than 6 months. The recommended phase II dose for
this regimen is 45 mg/m2172 h every four weeks.
In chapter 8 the influence of the fraction free drug of cisplatin and
carboplatin (CBDCA) on a human tumor cell line and bone marrow cells in vitro is
investigated in order to determine to what degree their difference of free fraction is
responsible for their difference in myelotoxicity. Various free drug fractions were
prepared by incubation of cisplatin or carboplatin in fetal calf serum for estimated
periods. After incubation the mixture was diluted to full culture medium (RPMI
1640 medium plus L0% fetal calf serum) offering solutions with different amounts
of free drug. A monoexponential relationship between the percentage of free drug
and incubation time in fetal calf serum was found for both cisplatin and
carboplatin. In the cytotoxicity assay it was found that the chemosensitivity of the
human small cell lung carcinoma cell line GLC. correlated with the fraction fiee
drug of cisplatin and carboplatin, however at a similar free drug fraction the
concentrations inhibiting survival by 50% (IC50) of carboplatin exceeded that of
cisplatin by a factor 10-19. In plasma of patients who have received cisplatin or
carboplatin, a respective free drug fraction of l0% and, 50% is reported in
literature. Tested at concentrations in the range of peak plasma concentrations after
standard doses, cisplatin was not found toxic to normal human bone marrow ceils
in a clonogenic assay (CFU-GM) at a (normal) free drug fraction of l0%, whereas
at free drug fractions of 50 and 90% it was considerably myelotoxic. Carboplatin
was found to be myelotoxic at a (normal) free drug fraction of 50% and also at 75
and 90%, also tested in the range of its peak plasma levels. It is conciuded that the
free drug fraction of cisplatin and carboplatin is a determining factor for drug
activity and the difference in protein binding between cisplatin and carboplatin at
least partly explains why the latter shows myelotoxicity whereas this is not very
pronounced with cisplatin in the clinical situation.
From our studies we conclude that the combination of differentiation induction
therapy with all-trans retinoic acid and cisplatin (or etoposide) chernotherapy, and
hyperthermic isolated limb perfusion with cisplatin, and the development of new
cisplatin analogues have the potential to circumvent cisplatin toxicity and
resistance.
The rational of combination therapy of differentiation induction with all-
trans retinoic acid followed by cisplatin (or etoposide) in vitro is twofold. All-trans
retinoic acid induces differentiation and enhances cisplatin and etoposide sensitivity
in a murine embryonal carcinoma cell line.
In experimental studies with parenteral l3-cis retinoic acid in rats, the described
formulation in alkaline solution is a good alternative to the rnore difficult
intravenous route.
Hyperthermic isolated limb perfusion with cisplatin allows high Pt levels in
the perfusate and leakage to the patients systemic circulation is relatively low. This
method allows considerable drug extraction by the perfused linrb during 60 min
perfusion and leads to detectable drug levels in the tumor. The maximurn tolerated
dose is 275 mg cisplatin.
l,obaplatin, which was found chemically stable for 12 h at roorll
temperature or for 24 h at 4"C at a concentration of 200 mglL in nonnal saline, is
a platinum analogue with a pharmacokinetic profile different frorn both cisplatin
and carboplatin. Its pharmacokinetics is characterized by rapid urinary excretion
and a high free drug fraction in plasma. Administered as a continuous infusion
over 72 h the dose limiting toxicity appears to be thrornbocytopenia and the
recommended phase II dose with continuous infusion is 45 mg/m2172 h every four
weeks.
For cisplatin and carboplatin the free drug fraction is the detennining factor
for drug activity in vitro. Their difference in myelotoxicity observed in the clinical
practice is at least partly explained by their difference in protein binding.
In this thesis selected strategies to circumvent cisplatin toxicity and
resislance were investigated in either in vitro or in phase I trials. Future
experiments hould focus on their applicability in clinical practice and on their

